Recent Advances in the Treatment Leading to Decline in the Overall Lung Cancer Mortality Rate

Release Date: 07-Aug-2020

In the past few years, there has been increasing cases related to lung cancer cases and deaths related to it. Therefore, controlling the cancer is one of the major concerns for majority of the researchers all around the world. But this has now been taken into consideration by many researchers as novel treatments are getting aligned for the lung cancer treatment. The study enrolled the patients having non-small cell lung cancer patients. Several novel treatments for the lung cancer treatment (NSCLC) have been aligned for it such as immune checkpoint inhibitors and target genetic changes but for the treatment of small-cell lung cancer, only few treatments have gotten far.


In the past few years, there has been a substantial improvement in the overall survival rate of the patients suffering from non-small cell lung cancer in case of men as well as women. The major reason that was found to be associated with improvement in the overall survival rate was decline in incidence and improvement in the treatment procedure.


However, some similar findings were associated with the small cell lung cancer case. It was also noted that in the past few years, the genetic testing for EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) mutations also increased in the last few years which however targeted newer treatments. It was estimated to increase the patient response outcome substantially. As immune checkpoint inhitors came late in the research sector, therefore, all the appreciation was achieved by to effective EGFR or ALK inhibitors. It has been observed that the arrival of therapies such as EGFR or ALK inhibitors and immune checkpoint inhibitors have impacted the patients’ at large level to much extent and the onhoing study highlights that same will be observed in the future cases too.

Need custom market research solution? We can help you with that too.